Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication Pneumagen has previously reported positive results from both Phase 1 and a clinical proof of concept Phase 2 Human Influenza Challenge study demonstrating the potential of NeumifilNew preclinical...

Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference  Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on...

Global Pediatric Antibiotics Market to Surpass US$ 7,759.3 Million by 2030, Says Coherent Market Insights (CMI) Seattle, Sept. 06, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global pediatric antibiotics market is estimated to be valued at US$ 6,478.9 million in 2022 and is expected to...